Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ Global Select · USD
156,61USD
+0,67 (+0,43 %)Stand 9. Nov., 21:00
Vorbörslich156,67+0,06 (+0,04 %)5:04 ET
Kennzahlen
- Eröffnung
- 156,13
- Vortag
- 155,94
- Tagesspanne
- 152,17 – 158,70
- 52 Wochen
- 152,17 – 479,79
- Volumen
- 3,3 Mio.
- Ø Volumen
- 2 Mio.
- Börsenwert
- 20,98 Mrd. $
- KGV
- 7,7
- Gewinn je Aktie (TTM)
- 19,80
- Dividendenrendite
- 0,0 %
- Beta
- 0,3
- Nächste Zahlen
- 11. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 3,71 Mrd. | 2,25 Mrd. | 1,83 Mrd. | 1,04 Mrd. | 844,29 Mio. |
| Herstellungskosten | 677,17 Mio. | 323,37 Mio. | 310,41 Mio. | 168,82 Mio. | 140,14 Mio. |
| Bruttogewinn | 3,04 Mrd. | 1,92 Mrd. | 1,52 Mrd. | 868,6 Mio. | 704,14 Mio. |
| Forschung und Entwicklung | 1,32 Mrd. | 1,13 Mrd. | 1 Mrd. | 883,02 Mio. | 792,16 Mio. |
| Vertrieb und Verwaltung | 1,21 Mrd. | 975,53 Mio. | 795,65 Mio. | 770,66 Mio. | 620,64 Mio. |
| Operatives Ergebnis | 501,58 Mio. | −176,89 Mio. | −282,18 Mio. | −785,07 Mio. | −708,65 Mio. |
| EBITDA | 631,44 Mio. | −178,85 Mio. | −258,24 Mio. | −926,56 Mio. | −661,56 Mio. |
| Nettogewinn | 313,75 Mio. | −278,16 Mio. | −440,24 Mio. | −1,13 Mrd. | −852,82 Mio. |
| Gewinn je Aktie (verwässert) | 2,33 | -2,18 | -3,52 | -9,30 | -7,20 |
Umsatz nach Segment
Produkte · FY 2025
- AMVUTTRA2,31 Mrd. $62,30 %
- Net revenues from collaborations553,37 Mio. $14,90 %
- GIVLAARI308,49 Mio. $8,31 %+20,56 %
- OXLUMO191,44 Mio. $5,15 %
- Royalty revenue174,02 Mio. $4,69 %
- ONPATTRO172,79 Mio. $4,65 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,73 Mrd. $74,82 %+174,53 %
- Europe405,9 Mio. $17,54 %+72,40 %
- Non-US Or Europe176,72 Mio. $7,64 %+69,27 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 7,7
- Kurs-Umsatz-Verhältnis
- 4,2
- Kurs-Buchwert-Verhältnis
- 5,8
- PEG
- 0,0
- Bruttomarge
- 77,3 %
- Operative Marge
- 19,5 %
- Nettomarge
- 54,3 %
- Verschuldungsgrad
- 0,4
- EV/EBITDA
- 16,4
- Eigenkapitalrendite
- 159,7 %
- Kapitalrendite (ROIC)
- 15,4 %
- Free-Cashflow-Rendite
- 2,4 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 81,8 % | 85,6 % | 83,0 % | 83,7 % | 83,4 % |
| Operative Marge | 13,5 % | −7,9 % | −15,4 % | −75,7 % | −83,9 % |
| Nettomarge | 8,4 % | −12,4 % | −24,1 % | −109,0 % | −101,0 % |
| KGV | 166,4 | -107,9 | -54,4 | -25,6 | -23,6 |
| Kurs-Umsatz-Verhältnis | 14,0 | 13,4 | 13,1 | 27,9 | 23,8 |
| Kurs-Buchwert-Verhältnis | 66,0 | 447,7 | -108,4 | -182,8 | 34,1 |
| Verschuldungsgrad | 1,6 | 19,3 | -5,9 | -8,3 | 1,7 |
| Liquidität 3. Grades | 2,8 | 2,8 | 3,1 | 3,5 | 4,0 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 51,71 Mrd. | 30,37 Mrd. | 24,4 Mrd. | 29,37 Mrd. | 20,26 Mrd. |
| EV/EBITDA | 81,9 | -169,8 | -94,5 | -31,7 | -30,6 |
| Eigenkapitalrendite | 39,8 % | −414,6 % | 199,5 % | 714,9 % | −145,0 % |
| Kapitalrendite (ROIC) | 13,7 % | −4,2 % | −9,7 % | −27,8 % | −23,7 % |
| Free-Cashflow-Rendite | 0,9 % | −0,1 % | 0,2 % | −2,1 % | −3,6 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +65,2 % | +23,0 % | +76,2 % | +22,9 % | +71,3 % |
| Bruttogewinn | +57,8 % | +26,8 % | +74,8 % | +23,4 % | +69,8 % |
| Operatives Ergebnis | +383,6 % | +37,3 % | +64,1 % | −10,8 % | +14,5 % |
| Nettogewinn | +212,8 % | +36,8 % | +61,1 % | −32,6 % | +0,6 % |
| Gewinn je Aktie | +206,9 % | +38,1 % | +62,2 % | −29,2 % | +3,5 % |
| Freier Cashflow | +1.192,7 % | −201,5 % | +106,8 % | +14,6 % | −4,8 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 37Kaufen
- 14Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
330,54
Durchschnitt · +111,06 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 5,44 Mrd. | 6,63 Mrd. | 7,78 Mrd. |
| Umsatz (Tief – Hoch) | 5,4 Mrd. – 5,5 Mrd. | 6,18 Mrd. – 8,01 Mrd. | 6,25 Mrd. – 9,81 Mrd. |
| Gewinn je Aktie (Ø) | 18,42 | 8,95 | 11,18 |
| Gewinn je Aktie (Tief – Hoch) | 8,12 – 22,60 | 7,21 – 11,05 | 5,24 – 27,47 |
| Analysten | 15 | 16 | 17 |
Letzte Änderungen
- Truist Securities2. Nov. 2026Buy → Hold
- Barclays2. Nov. 2026Overweight
- Canaccord Genuity2. Nov. 2026Buy
- RBC Capital30. Okt. 2026Outperform
- Raymond James30. Okt. 2026Strong Buy → Outperform
- UBS30. Okt. 2026Buy
- TD Cowen30. Okt. 2026Buy
- Bernstein30. Okt. 2026Outperform → Market Perform
Quartalszahlen
Nächste Zahlen: 11. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 1,66 | 1,63 | 0,87 | 1,16 | 0,56 | -0,54 | -0,89 | -0,62 |
| Gewinn je Aktie · Tatsächlich | 16,26 | 1,21 | 1,51 | 0,82 | 1,84 | -0,51 | -0,44 | -0,65 |
| Abweichung | +879,52 % | −25,77 % | +73,17 % | −29,31 % | +227,99 % | +6,20 % | +50,56 % | −4,84 % |
| Umsatz · Tatsächlich | 1,46 Mrd. | 1,29 Mrd. | 1,17 Mrd. | 1,1 Mrd. | 1,25 Mrd. | 773,69 Mio. | 594,19 Mio. | 593,17 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 100,97 %
- Investoren mit 13F-Meldung
- 830
Größte Investoren
- FMR LLC11,28 %15,02 Mio.
- CAPITAL WORLD INVESTORS8,36 %11,14 Mio.
- BLACKROCK, INC.8,19 %10,91 Mio.
- CAPITAL RESEARCH GLOBAL INVESTORS7,32 %9,75 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,91 %6,54 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,53 %6,03 Mio.
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC.4,23 %5,64 Mio.
- INVESCO LTD.2,82 %3,75 Mio.
Insider-Geschäfte
- SUPRAN BRYAN2. Okt. 2026 · officer: EVP, CLO and SecretaryVerkauf1758 Aktien · 226,88
- Greenstreet Yvonne19. Sept. 2026 · director, officer: Chief Executive OfficerKauf107 Aktien
- PYOTT DAVID E I1. Juni 2026 · directorKauf3830 Aktien
- PYOTT DAVID E I1. Juni 2026 · directorVerkauf921 Aktien · 297,71
- PYOTT DAVID E I1. Juni 2026 · directorVerkauf1175 Aktien · 298,91
- PYOTT DAVID E I1. Juni 2026 · directorVerkauf1222 Aktien · 299,87
- PYOTT DAVID E I1. Juni 2026 · directorVerkauf495 Aktien · 300,72
- PYOTT DAVID E I1. Juni 2026 · directorVerkauf17 Aktien · 302,65
Vergleichbare Unternehmen
Über das Unternehmen
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Führung
- Yvonne L. GreenstreetChief Executive Officer & Director
- Pushkal GargExecutive VP & Chief Research & Development Officer
- Jeffrey V. PoultonChief Financial Officer & Executive Vice President
- Tolga TangulerExecutive VP & Chief Commercialization Officer
- Kevin Joseph FitzgeraldExecutive Vice President, Chief Scientific Officer and Head of Early Research & Early Development
- Bryan Andrew SupranChief Legal Officer
- CEO
- Yvonne L. Greenstreet
- Mitarbeitende
- 2.500
- Hauptsitz
- Cambridge, MA, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 1. Juni 2004
- Website
- alnylam.com
Nachrichten
- Business Wire · 9. Nov., 10:50Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
- Seeking Alpha · 6. Nov., 2:05Brown Advisory Large-Cap Sustainable Growth Strategy Q3 2026 Holdings Performance
- Business Wire · 4. Nov., 17:15Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
- Business Wire · 3. Nov., 8:30Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
- 247 Wallst · 2. Nov., 8:13Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More
- Zacks Investment Research · 30. Okt., 12:06ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
- GlobeNewsWire · 29. Okt., 17:40Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop
- Seeking Alpha · 29. Okt., 13:59Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
- MarketBeat · 29. Okt., 13:03Alnylam Pharmaceuticals Q3 Earnings Call Highlights
- Zacks Investment Research · 29. Okt., 11:31Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.